Charles Morgan is a conviction investor with major successes in shale gas and biopharma. He was the first funder of Clarity Pharmaceuticals (ASX: CU6) which has reached a valuation of more than A$2bn. He has a proven track record in identifying early stage commercial opportunities and acting as a corporate catalyst, acquiring strategic assets and positions, partnering with regional and technology experts, securing teams of appropriate executives and funds to build and develop projects and companies. He has a number of successful exits to his name.

Charles started his career in futures broking in London with M.L. Doxford & Co and left to join merchant bank Morgan Grenfell Limited in Sydney, Australia before moving to broking with ANZ McCaughan Dyson Limited in Melbourne and London. He then joined BZW Securities Limited in London before going back to Australia to form Morgan McFarlane a licensed securities dealer which raised equity funds for mining and oil exploration companies.

He was awarded an honorary Doctor of Science from Curtin University for his contribution to the commercialisation of biotechnology.